SILVER SPRING, Md. and SINGAPORE, Singapore, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today its wholly-owned subsidiary, Austrianova Singapore Pte Ltd (ASPL) has just received notice that the U.S. based Personal Care Products Council (PCPC) has assigned the International Nomenclature Cosmetic Ingredient (INCI) name Gel8 (pronounced gelate), to the company's proprietary cell encapsulation materials. The PCPC determined, through the International Nomenclature Committee, to provide the Gel8 name assignment to ASPL. As a result, Gel8 will now be included as a new product in the International Cosmetic Ingredient Dictionary & Handbook as well as in the next update of the Cosmetic industry's International Buyer's Guide. The combined Dictionary/Handbook contains more than 19,100 INCI labeling names for the United States, European Union, Japan and other countries. There are many aspects of cosmetics safety and labeling overseen by the FDA and other regulatory bodies around the world. Receiving the INCI designation allows for greater potential use in cosmetics throughout the US and the world. Dr. John Dangerfield, Chief Operating Officer of ASPL, said, "We are thrilled that our work has enabled us to receive this designation. Most importantly, holding the INCI name is necessary for product safety and visibility as well as a significant step forward for using the Cell-in-a-Box® and Bac-in-a-Box® technology throughout the cosmetics industry. We see applications of the technology that expand from the cancer field well into other areas of medicine, cosmetics, and nutrition, among others, and see this designation as one of the first important steps." The Chief Executive of Nuvilex, Dr. Robert Ryan, stated, "I was extremely impressed by what I saw while visiting ASPL in Singapore last week. I'm certain the effort they put forward to receive assignment of the INCI name Gel8 for our live cell components from our Cell-in-a-Box® and Bac-in-a-Box® patented encapsulation technology from the Personal Care Products Council is a significant move forward. All of the effort by the lab over the past year will allow us to expand the use of the technology and ultimately be able to produce products for other markets including the cosmetics market. The ability to receive the INCI designation also demonstrates how broad this platform technology we are developing together with ASPL is."
About NuvilexNuvilex, Inc. (OTCQB:NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. A great deal of work is ongoing to move Nuvilex and its Austrianova Singapore subsidiary forward. This was clearly apparent during Dr. Ryan's recent trip to Singapore completed last week. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology. The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494 Safe Harbor Statement This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.
CONTACT: Investor Relations Contact: Marlin Molinaro Marmel Communications, LLC Ph: (702) 434-8692 email@example.com